Player Avatar zzlangerhans (99.85) Submitted: 11/7/2012 11:31:39 PM : Outperform Start Price: $24.80 VPHM.DL Score: +70.63

Nothing much to see here except some correction green thumbing. ViroPharma is getting dragged down along with most other biopharma mid caps despite the impressive growth in Cinryze sales. Vancocin revenues are shrinking to nothing but that was expected once the generic serpent hatched. The share price bottomed at 20 after the bad news broke about generics and then rose over 30 at the height of September's biopharma fever. The stock may well be headed back to 20 if broad market weakness continues, but at some point the winds will shift again.

Featured Broker Partners